The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.53
Bid: 1.53
Ask: 1.60
Change: -0.002 (-0.13%)
Spread: 0.07 (4.575%)
Open: 1.53
High: 1.53
Low: 1.53
Prev. Close: 1.567
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: TBC Bank swings to first quarter profit

Tue, 18th May 2021 11:01

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

----------

SMALL-CAP - WINNERS

----------

TBC Bank Group PLC, up 5.6% at 1,136.00 pence, 12-month range 700p-1,350p. The Georgian banking group swings to first quarter consolidated net profit of GEL153.0 million - equivalent to around GBP31.7 million - from GEL57.0 million loss year-on-year. "The improving business environment, coupled with our strong data analytical capabilities and focus on digital, fills me with confidence that in 2021 we will be able to return to our pre-Covid profitability levels and we will assess the potential for future dividends subject to macroeconomic developments and containment of Covid-19 pandemic," company says.

----------

SMALL-CAP - LOSERS

----------

Hemogenyx Pharmaceuticals PLC, down 18% at 1.78p, 12-month range 1.73p-15.4p. The biotechnology company enters into agreement with Mint Capital Advisors Ltd for the redemption and sale of all outstanding GBP8.1 million convertible unsecured loan notes issued to Mint in February. Following completion, there will be no convertible loan notes outstanding and the facility entered into with Mint will terminate. "The directors have determined that the redemption and sale are in the best interests of the company and its shareholders. The company will be able to maintain its level of operations as it moves its product candidates forward to clinical trials, updates about which will be provided to shareholders in due time," company says.

----------

Nostrum Oil & Gas, down 12% at 11.5p, 12-month range 7.43p-16p. Reports first quarter revenue of USD46.2 million, down from USD60.4 million year-on-year, while earnings before interest, taxes, depreciation and amortisation falls to USD26.8 million from USD31.7 million.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
23 Oct 2019 08:41

Hemogenyx Inks USD75,000 Research Deal With Undisclosed Global Firm

Hemogenyx Inks USD75,000 Research Deal With Undisclosed Global Firm

Read more
30 Sep 2019 16:51

Hemogenyx Interim Loss Widens But CDX Antibody Work Progresses

Hemogenyx Interim Loss Widens But CDX Antibody Work Progresses

Read more
19 Oct 2018 08:26

Hemogenyx enters collaboration agreement with Orgenesis

(Sharecast News) - Biopharmaceutical group Hemogenyx has entered into a collaboration agreement with cell therapy outfit Orgenesis to further commercialise its humanised-mouse drug model.

Read more
15 Oct 2018 08:32

Hemogenyx inks lupus collaboration with Johnson and Johnson

(Sharecast News) - Biopharmaceutical group Hemogenyx has entered into a collaboration agreement industry giant Johnson and Johnson to develop a model of systemic lupus erythematosus, the most common form of Lupus.

Read more
3 Apr 2018 13:25

Hemogenyx Pharmaceuticals Appoints Marc Feldmann As Executive Chairman

LONDON (Alliance News) - Biotechnology company Hemogenyx Pharmaceuticals PLC said on Tuesday it has appointed Marc Feldmann as executive chairman, with effect next will be who

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.